Obesity Management

A secondary analysis of a cluster RCT indicated the Texas Sprouts intervention led to improvements in glucose control and reduced LDL-C in high-risk schoolchildren.

MAFLD-lean and MAFLD-diabetes subgroups recorded a higher risk of all-cause and disease-specific mortality compared to the MAFLD-overweight/obese group.

Published in Pediatrics on January 9, the document represents the first comprehensive guideline from the American Academy of Pediatrics in more than a decade and the first ever on the evaluation and management of obesity in those aged 2 years and older.

Using data from 18 trials with more than 1400 participants, a systematic review and meta-analysis offer clinicians an overview of the effects of SGLT2 inhibitor use on body composition in people with type 2 diabetes.

Using data from more than 25,000 preschool-aged children in Sweden provides an overview in trends of weight gain and BMI changes that may have impacted pediatric populations during the COVID-19 pandemic.

There was no differences observed in total weight loss at both 6 and 18 months in the fecal microbiota transplantation and placebo groups.

A continued discussion with Dr. Bays on anti-obesity therapies down the line and where they might be in the near future.

Anti-obesity medications have the potential for significant weight reduction, but the development of newer agents may lead to an even greater change in obesity care.

In her SDPA 2022 presentation interview, Dr. Katta explores gaps in knowledge regarding the connection between skin disease and dietary health, as well as ways to address these concerns.

The emergence of weight loss agents like tirzepatide and an FDA Fast Track designation announced days earlier, endocrinologists were excited to discuss what's happening at Pri-Med Midwest 2022.

As the age of diagnosis for pre and type 2 diabetes continues to decrease, Dr. Tina Thethi believes in focusing on reducing risk factors to prevent further complications.

The ongoing buzz around GLP-1 RAs, like semaglutide, and now the GIP combination drug tirzepatide, reached a summit at Pri-Med Midwest 2022.

"When you decrease the weight, that also improves the metabolic parameters. The A1c goes down, it helps bring the fasting glucose down, including even liver parameters," she explained.

Semaglutide (Wegovy) has drawn attention for its indication of weight loss. Recently, however, the focus has shifted to the data surrounding tirzepatide.

Despite the efforts to increase the affordability of GLP-1 receptor agonists cost-effectiveness is still a barrier for many patients living with diabetes looking for effective therapies.

Primary Care Physicians (PCPs) play a crucial role in endorsing lifestyle counseling and facilitating integrative care for their patients.

"Less than 2 or 3% of individuals with obesity—who are candidates for pharmacotherapy—actually receive a medication," Dr. Robert Kushner explains in an interview.

The risk of primary composite cardiovascular outcomes was reduced by 47%, while the risk of secondary cardiovascular disease outcomes was reduced by 50% in patients with bariatric surgery compared to nonsurgical patients.

The risk of cirrhosis increased supramultiplicatively in patients with obesity, with excessive drinking, and who were homozygous carriers.

The association between cumulative BMI and risk of NAFLD was more pronounced in women and younger participants.

The inter-relationship of HPCs, HSCs, and macrophages was influenced by the stage of fibrosis, but not BMI.

A conversation on advancements in diabetes, the rising cost of insulin, and advice regarding disease management.

Early time-restricted eating was more effective for losing weight than eating over a window of ≥12 hours, but did not affect body fat.

Dr. Kushner discusses obesity as a risk factor for CVD and how preventive cardiologists can better target weight management to support patient health.

The new recommendation acknowledges the role of disease-preventive behaviors that can be taken on by approximately 12% of the US population.

Trends in adjusted obesity prevalence increased over 20 years, particularly in adolescents from low-socioeconomic status households.

Preventable factors including obesity, hypertension, and physical activity are disparately impacting the rate of dementia among people of color.

Vaccine effectiveness was slightly lower in patients with underweight, who also have the lowest levels of vaccine uptake across all ages.

The approval, which was was supported by data from a 56-week trial involving 223 obese individuals 12-17 years old, recommended the capsules be used in conjunction with a reduced-calorie diet and increased physical activity.

A look into the top discussions on the management of obesity at the 2022 OMA Spring Meeting, from new agents to treating special populations.